Medicine advances whenever the invisible becomes visible.

Raydiant is bringing oxygen monitoring to the last patient not receiving it: the fetus.

Seeing through uncertainty.

Closing one of obstetrics' most important information gaps.

Approximately 3.6 million babies are born in the United States each year.¹ Yet during labor, clinicians often face ambiguous fetal heart rate patterns without a direct measure of fetal oxygenation. Critical decisions are made using incomplete information. Raydiant Oximetry is developing fetal pulse oximetry technologies to bring greater clarity when it matters most.

1. National Vital Statistics Reports, Vol. 75, No. 2, "Births: Final Data for 2024."

Electronic fetal monitoring categories, shown clearly

Where Raydiant brings clarity during labor and delivery.

Most decisions happen between normal and abnormal.

Every fetal heart rate tracing falls into one of three categories. Category II is the indeterminate middle ground.

More than 80% of labors include periods of Category II heart rate tracings², where today’s monitoring can leave important questions unanswered. Raydiant adds objective fetal oxygen information when it matters most.

2. NIH National Library of Medicine, PubMed, "Management of the Category II Fetal Heart Rate Tracing."

A new era in fetal monitoring.

Raydiant is developing two complementary technologies designed to bring fetal pulse oximetry into clinical decision-making. Together, they aim to provide clinicians with new insight during labor, whether through direct measurement or non-invasive monitoring.

Nirah^™

Direct fetal pulse oximetry visibility.

Nirah is Raydiant's first fetal oximetry platform, designed to integrate into today's labor and delivery environment and provide direct fetal pulse oximetry information when fetal monitoring is most challenging.

Nirah is designed to rest directly on the fetus’s cheek once the membranes have ruptured. The product will include the latest sensor technology, along with algorithms developed from many hours of direct fetal pulse oximetry data being collected through ongoing clinical studies.

Longer-term, Nirah will be complementary to Lumerah for certain patient types, such as women with a high BMI, where external monitoring might not be indicated.

Lumerah^™

The external oxygen monitoring vision.

Lumerah represents Raydiant's longer-term platform vision, extending the possibilities of fetal oxygen status across additional patients, settings, and clinical applications.

The Lumerah sensor is placed on the mother’s abdomen and non-invasively detects fetal pulse oximetry signals. The technology combines cutting-edge biophotonics and machine learning to monitor fetal oxygenation, with the potential to enable continuous fetal monitoring during the third trimester and at home.

The product is currently in development, utilizing advanced computer modeling and simulations based on IDE-approved clinical studies to demonstrate Proof of Principle for the technology.

Clarity has clinical and economic weight.

In labor and delivery, clinicians make critical decisions with the information available to them, always focused on the well-being of mother and baby.

But when fetal oxygen status is unknown, the clinical picture can remain incomplete. Greater physiological clarity may help care teams better understand fetal status, support timely intervention when needed, and reduce uncertainty.

Because when outcomes are questioned after the fact, context matters.

Clarity benefits everyone involved. It helps clinicians make more informed decisions, supports communication with families, and provides a richer understanding of the clinical picture.

Raydiant is built to make fetal oxygen status visible.

Raydiant Oximetry brings together clinical insight, engineering discipline, and a focused mission: giving care teams a clearer view of fetal oxygen status when it matters most.